Pharmala Biotech Holdings Inc. (MDMA.CN) Research

Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.

Market snapshot

Symbol
MDMA.CN
Price
$0.14
Day change
+3.70%
Market cap
$15.2M
P/E ratio
-9.34x
52-week range
0.085-0.195
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BetterLife Pharma Inc. (BETR.CN)
  • Britannia Life Sciences Inc. (BLAB.CN)
  • Comprehensive Healthcare Systems, Inc. (CHS.V)
  • Glow Lifetech Corp. (GLOW.CN)
  • Hemostemix Inc. (HEM.V)
  • Medicure Inc. (MPH.V)
  • Marvel Biosciences Corp. (MRVL.V)
  • PharmaTher Holdings Ltd. (PHRM.CN)

Open Pharmala Biotech Holdings Inc. (MDMA.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.